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Modulation of plasma and platelet vasopressin by cardiac function in
patients with heart failure. Two groups of patients with congestive heart
failure were studied, one with elevated (Group 1) and another (Group II)
with suppressed plasma concentrations of vasopressin. The mean
plasma arginine vasopressin (AVP) concentration in the 17 patients in
group I was 3.1 0.4 pg/mliter whereas the eight patients in group II
had plasma concentration <0.5 pg/muter. Platelet AVP concentrations
were also higher in the Group I than Group II patients (7.8 1.5 vs. 2.2
0.7 pg/mliter, P < 0.001). Plasma effective osmolality (262 vs. 268
mOsm/kg H20, P <0.05) and plasma sodium concentration (134 vs. 137
mEq/liter, P < 0.05) were lower in Group I. The Group I patients had
a lower cardiac index (Cl, 1.9 vs. 2.5 liter/min/m2, P <0.05) and higher
pulmonary capillary wedge pressure (PCWP, 30 vs. 22 mm Hg, P <
0.02), plasma renin activity (4.4 vs. 2.0 nglmliter/hr, P < 0.01), and
plasma aldosterone (74 vs. 10 ng/dliter, P < 0.001) than the Group II
patients. The Group I patients also excreted a smaller percentage of a 15
mliter/kg waterload (31 vs. 57%, P < 0.005). Group! patients then were
treated with agents to decrease cardiac afterload, either captopril or
prazosin. CI increased (1.9 to 2.1 liter/min/m2, P < 0.001) and PCWP
decreased (30 to 27 mm Hg. P < 0.001). This improved cardiac
performance was associated with enhanced water excretion (31 vs.
52%, P < 0.001) and decreased minimal urinary osmolality (375 vs. 208
mOsm/kg H20, P <0.001). Plasma AVP (3.1 vs. 1.8 pglmliter, P < 0.01)
and platelet AVP (7.8 vs. 5.1 pg/muter, P < 0.005) were significantly
lower after vasodilator therapy. Plasma AVP and platelet AVP were
found to be significantly correlated with minimal urinary osmolality
during the waterload (respectively, r = 0.62, P < 0.001; r = 0.54, P <
0.001). There was no change in glomerular filtration rate. In the Group
I patients, in the control condition as well as after vasodilator therapy,
plasma AVP decreased with plasma osmolality during the waterload,
suggesting some preservation of the osmoregulation of AVP with a
lower osmotic threshold. These results support a role of impaired
cardiac function in the non-osmotic stimulation of vasopressin in
patients with congestive heart failure. Improved cardiac function sec-
ondary to afterload reduction diminishes this non-osmotic release of
vasopressin.
Early studies using bioassay techniques to examine the
potential role of plasma vasopressin in the hyponatremia of
congestive heart failure (CHF) provided conflicting results
[1—4]. More recent studies examining plasma vasopressin levels
by radioimmunoassay, however, have demonstrated elevated
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concentrations in the majority of patients with cardiac failure
and hyponatremia [5—10]. Earlier studies have suggested that
some hyponatremic cardiac patients responded normally to a
waterload by the prompt onset of water diuresis [12]. This
qualitatively normal response to water administration was an
indirect suggestion of a functioning osmoreceptor mechanism
operating at a lower setting [12]. More recently, AVP secretion
was found to respond in an exaggerated fashion to osmotic
loading in patients with CHF undergoing radiological proce-
dures with radioconstrat hyperosmolar agents [11]. It is not
known, however, whether impaired cardiac function is respon-
sible for the non-osmotic release of vasopressin and thereby
alters the characteristics of the osmotic release of vasopressin.
In the present study, therefore, the renal water excretion and
plasma vasopressin concentration in response to an acute
waterload were examined in patients with congestive heart
failure before and after improvement in cardiac performance by
afterload reduction with vasodilator therapy. In the 17 patients
with elevated plasma vasopressin concentrations, in spite of
hypo-osmolality and hyponatremia, afterload reduction im-
proved cardiac performance and led to enhanced water excre-
lion and improved suppressibility of plasma and platelet vaso-
pressin concentrations. These results are therefore compatible
with cardiac function as a modulator of the non-osmotic release
for vasopressin release in patients with congestive heart failure.
This effect of cardiac function on the modulation of vasopressin
release could be termed a variety of "resetting" of the
osmoreceptor.
Methods
Twenty—five patients (19 men and 6 women) with severe
congestive heart failure (New York Heart Association class
III—IV) were studied. The patients' mean age was 63.1 1.7
years (range 45 to 75 years). Twenty—three patients had coro-
nary artery disease and two patients had valvular heart disease.
Prior to their entry into this study, all subjects had repeated
admissions for pulmonary edema and were found to be resistant
to the standard therapy with cardiac glycosides and diuretics.
The patients were admitted and ingested a diet containing 35 to
50 mmoles of sodium per day for five days. Water intake was
restricted to 800 mliter of free water per 24 hr. The patients
were then transferred to the coronary care unit. Digitalis and
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diuretics were discontinued for 24 hr prior to each waterload
procedure. No patients received vasodilators prior to the study.
Waterloads and hemodynamic measurements
Patients received a waterload equal to 15 muter/kg of body wt
on day 1 (Cont); then after two days of vasodilator therapy
(captopril or prazosin) a second waterload (Exp) was adminis-
tered. Hemodynamics were monitored before and hourly for
five hours after each waterload in the following manner. After
an overnight fast, a 7F triple—lumen, flow—directed, balloon—tip-
ped thermodilution catheter (Edwards Laboratories, Santa
Ana, California, USA) was introduced transcutaneously
through the internal jugular vein by the Seldinger Technique
and advanced to a pulmonary "wedge" position according to
pressure tracings. Pulmonary arterial, right atrial (RAP) and
pulmonary capillary wedge pressures (PCWP) were monitored
by using a Gould—Statham P231d transducer positioned at the
mid-axillary line, and were recorded on an Electronic for
Medicine VR 6 Photographic Recorder. Cardiac output was
measured by means of the thermodilution technique with iced
5% dextrose in water. Measurements of cardiac output were
obtained by use of a computer (model 9520, Edwards Labora-
tories). Systemic arterial blood pressure (MAP) was obtained
through an intraarterial radial catheter or by the standard cuff
technique. Baseline hemodynamic measurements were ob-
tained at least one hr after the positioning of the Swan Ganz
catheter. Thereafter, a 15 mliter/kg of body wt waterload
consisting of 5% glucose in water was administered intrave-
nously over 45 to 90 mm, and renal water excretion was
monitored over the next five hours as previously described
[13—15]. No adverse symptoms like nausea occurred during or
after the waterload administration in any of the patients tested.
Blood was drawn every hour through the arterial line for
measurements of electrolytes, osmolality, blood urea nitrogen,
glucose, creatinine, protein and albumin. Samples were also
obtained at the beginning of each waterload for the measure-
ments of arterial blood gases. Samples were also taken for
measurements of plasma AVP and platelet AVP, plasma renin
activity (PRA) and plasma aldosterone (PA). Urine was ob-
tained by spontaneous voiding every hour. The volume of each
collected urine was recorded and urine was analyzed for
electrolytes, osmolality, urea nitrogen and creatinine.
Derived hemodynamic values were calculated as follows:
• 2 cardiac outputCI (liter/min/m)
body surface area
-
stroke volumeStroke volume index (SVI) =
body surface area
Systemic vascular resistance (SVR):
SVR = 80 (mean arterial pressure—right atrium pressure)
cardiac output
Left ventricle stroke work index (LVSWI):
LVSWI = SVI (mean arterial blood pressure—mean pulmo-
nary capillary wedge pressure) 0.0136
Vasodilator treatment
The vasodilator therapy was administered in the following
manner. In a random manner, the patients were given either
prazosin in increasing doses (0.5, 1, 2, 3, 4, 5 mg) or captopril in
increasing doses (6.25, 12.5, 25 mg) every six hours until one of
the following end points was reached: 1) a decrease in MAP
between 10 and 20 mm Hg; 2) a decrease in systolic arterial
blood pressure to a value below 100 mm Hg; 3) a maximal dose
of 5 mg of prazosin or of 25 mg of captopril. Intravenous
furosemide was given after the end of the first waterload study
and again 24 hr prior to the second waterload as necessary to
maintain urine output within 500 muter of intake.
Arginine vasopressin radioimmunoassay
Blood samples collected in chilled EDTA tubes were centri-
fuged at 4°C at 3000 rpm for 20 mm and plasma for the AVP
determination was extracted by a modification of the acetone
method described by Robertson et al [161 and Dun-,
Stamoutsos, and Lindheimer [17]. Briefly, 1 mliter of thawed
sample is mixed with 2 mliter of cold acetone and centrifuged.
The supernate is then mixed with 5 mliter of cold petroleum
ether and recentrifuged. Tubes are then frozen to —80°C and
the top phase (liquid) is discarded. The bottom phase is then
thawed and evaporated to dryness at room temperature under a
stream of cold air (Concevator sample concentrator, E-C-
Apparatus Corp. St. Petersburg, Florida, USA). The dry resi-
due is reconstituted in 750 diter of a 0.1% bovine albumin
solution (Miles Laboratories, Elkhart, Indiana, USA) also
containing 0.1% sodium azide (pH is adjusted to 7.2 with
Triz-Base).
The assay buffer was 0.1 M sodium phosphate at pH 7.6 and
contained 0.3% (wt/vol) NaCI, 0.1 g!I00 g bovine serum albu-
min (Miles) and 0.1 g/lOO g of sodium azide. Standard curves
were prepared with purified AVP (Batch No. BAA 252, 1 mg =
450 lU, Ferring Pharmaceuticals, S-200 62, Malmo, Sweden) in
quantities that ranged from 0.05 to 10 pg per assay tube. 200
sliter of standards in buffer or 200 piiter of reconstituted plasma
extract, and 200 piiter of antiserum in buffer were incubated in
triplicate for the standards and in duplicate for the unknown, for
two days at 4°C; then 100 diter of tracer (1200 to 800 cpm) was
added and incubation was carried on for an additional three
days. Free and bound fractions were then separated by a
dextran—charcoal method.
Extracts of plasma from four patients with complete central
diabetes insipidus failed to displace tracer and were used
regularly as controls.
The tracer used was vasopressin-8-arginine ['251]-monoiodi-
nated (New England Nuclear, Boston, Massachusetts, USA)
with a high specific activity (1820 to 2200 Ci/mM). Non-specific
binding was always <3%.
The antiserum (AS-2849) used was at a final dilution of 1/2.5
x 106. The cross reactivity of this antiserum was less than 8%
for lysine—vasopressin and less than 4% for arginine—vasotocin.
Sensitivity of the assay using this antiserum in our laboratory
was always 0.1 pg/assay tube and the 50% displacement was 1.2
pg/tube. Cold vasopressin was added to the plasma of patients
with central diabetes insipidus and the mean recovery was 102
4%. Intraassay coefficient of variation for AVP plasma
values between 2 and 5 pglmliter was 5 to 13%. Mean interassay
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coefficient of variation for plasma vasopressin values between
0.5 and 18 pg/muter was 20% (0.2 0.12, mean SD).
Characteristics of this antiserum and radioimmunoassay have
been described in a preliminary communication [18].
Since platelet vasopressin has been reported to be altered in
the opposite direction of plasma vasopressin in patients with
cardiac failure [8], plasma arginine—vasopressin was measured
on platelet—poor and platelet—rich plasma. 'Platelet fraction"
vasopressin was obtained according to a modification of the
method described by Preibisz et al [8]. Blood was drawn in
EDTA containing tubes and was centrifuged for 20 mm at 1000
rpm. 100 piiter of plasma was then taken and the platelet
content of this fraction was determined (Coulter Counter,
Model P-64, Coulter Electronics Inc., Edison, New York,
USA). One mliter of plasma was then frozen at —20°C and later
extracted according to the above described acetone—petrol—eth-
er method. One hundred samples of plasma were randomly
obtained during these studies and their platelet content was
288,000 15,000/diter; this fraction is called vasopressin
fraction in platelet—rich plasma. By contrast, the same plasma
samples centrifuged at 3,000 rpm contained 31,000 2,500
platelets/piiter, this fraction is called plasma arginine vasopres-
sin (Pavp) in platelet—poor plasma. The platelet—rich vasopres-
sin fraction, —Pavp, is termed platelet fraction vasopressin
(platAVP). In preliminary experiments, we found that Pavp and
PIatAVP were undetectable (< 0.5 pg/mliter) in four patients
with untreated complete central diabetes insipidus (DI). These
DI patients then received an infusion of arginine—vasopressin
and both Pavp and PIatAVP could then be measured in plasma.
Measurements of plasma renin activity (PRA) and plasma
aldosterone (PA) by radioi,nmunoassays
PRA. Blood samples were collected in chilled EDTA tubes,
centrifuged at 4°C at 3000 rpm for 20 mm and kept at —20°C
until assay. Incubation for generation of angiotensin I was
carried out at pH 6.0 for two hours with 8-hydroxyquinoleine.
Plasma renin activity was measured as ng of angiotensin I per
mliter of plasma per hour of incubation [19].
Aldosterone assay. Plasma aldosterone was measured by a
commercial kit (Abbott Diagnostics, Diagnostic Products,
North Chicago, Illinois, USA) [20]. The antiserum used is
highly specific and has virtually no cross reactivity with other
steroids or lactone.
Other analytical procedures and calculations. Plasma
osmolality (Posm) was determined in duplicate on 250 sl
samples by freezing—point depression (Advanced Instrument
Osmometer 3D!!; Advanced Instruments, Inc., Needham
Heights, Massachusetts, USA). Sensitivity of the instrument is
1 mOsm and its coefficient of variation at 290 mOsm is
0.5 1%. Plasma for osmometry was always collected on heparin
and recommendations from the literature were strictly followed
[16]. Plasma effective osmolality (Eosm) was calculated accord-
ing to the formula:
[Glucose (mgldliter) BUN (mg/dliter)]Eosm = Posm — +
18 2.8
Plasma sodium was measured with a sodium specific elec-
trode (Nova Biomedical, Newton, Massachusetts, USA).
Blood urea nitrogen and plasma glucose were measured by
autoanalyzer. Creatinine was determined on a Beckman Creat-
mine Analyzer (Beckman Instruments, Inc., Fullerton, Califor-
nia, USA). Arterial blood gases were measured by standard
methods. Free water and osmolar clearances were calculated
each hour during the waterload procedures. Statistical analysis
was performed by Student's t-test for unpaired and paired
comparisons and by linear regression analysis. A multiple
regression analysis was also performed with the SPSS pro-
grams.
This research protocol was approved by the appropriate
institutional ethics board and all subjects gave informed written
consent to their participation to this study.
Results
Water excretion and hemnodynamic characteristics prior to
the vasodilator therapy
Abnormal water excretion was clearly demonstrated in all 25
patients studied and a mean of 39.7 3.9% of the control 15
mliter/kg of body wt waterload was excreted during the five hr
study. The mean glomerular filtration rate was 55 4.6
mliter/min/l .73 m2. The impaired water excretion was associ-
ated with hyponatremia (134.5 0.8 mEq/liter), low basal
Eosm (264.1 1.5 mOsm/kg H20) and a minimum urinary
osmolality (mm Uosm) of 303.3 32.7 mOsm/kg H2O. Posm
was not found to be severely decreased in these patients
because of an elevation of plasma urea nitrogen (27.2 2.0
mg/dliter)as well as of an elevation of plasma glucose (209 22
mgldliter). Because Eosm has been determined to be the major
determinant of AVP release [16], only Eosm will be considered.
Hemodynamic measurements confirmed the severity of the
alteration in cardiac performance in all the 25 patients studied,
since mean CI was 2.08 0.2 liters/min/m2; mean pulmonary
capillary wedge pressure (PCWP) was 27.5 1.5 mm Hg and
right atrium pressure (RAP) was 12.2 0.9 mm Hg.
Classification of cardiac patients according to their Pavp
levels
As previously reported [5], cardiac patients were then clas-
sified according to whether they had detectable (> 0.5
pg/mliter), or undetectable (< 0.5 pg/mliter) basal Pavp. Sev-
enteen cardiac patients (Group I) had high basal Pavp (> 0.5
pg/mliter, mean: 3.09 0.42 pg/mliter); the remaining eight
patients (Group II) had suppressed basal Pavp (< 0.5 pg/mL).
The increased Pavp of Group I patients occurred in spite of
tower Eosm and PNa than Group II patients (respectively 262.3
1.9 vs. 268 2 mOsm/kg H20; 133.5 1.0 vs. 136.5 0.9
mEq/liter, both P <
.05, Table 1). The relationship between
Eosm and Pavp (Fig. 1) or between PNa and Pavp (Fig. 2) for
these two cardiac groups was compared against the 99% confi-
dence limit of the regression line describing 19 normal subjects.
The 19 normal subjects were studied in our laboratory during a
standard waterload and during a hypertonic saline infusion. The
Group I patients had high levels of basal Pavp as compared to
their Eosm or PNa. By contrast, Group II patients had appro-
priately undetectable basal Pavp for their Eosm and PNa. Basal
Plat AVP was also found to be higher in Group 1(7.78 1.5
pg/mliter) than in Group 11(2.19 6.7 pg/mliter, P < .005)
(Table 1). Furthermore, in Group I patients, the high Pavp
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Table 1. Plasma sodium (PNa), effective plasma osmolality (Eosm), vasopressin levels and characteristics of water excretion in the two groups
of cardiac patients during the control waterload study.
Group I, N = 17 Group LI , N = 8
Time post H20 load, basal basal
hours (0) 1 2 3 4 5 (0) 1 2 3 4 5
PNa, mEqlliter 133.5* 129.4 130.9 131.6 132.4 133.1 136.5 132.2 134.7 135.7 135.4 136.2
±1.0 ±0.7 ±1.1 ±1.0 ±1.1 ±1.1 ±0.9 ±1.8 ±1.5 ±1.5 ±1.9 ±1.67
Eosm, mOsm/kg H20 262.3* 252.9 255.2** 257.1* 256.8** 258** 268 258.6 262.8 262.9 264 264.2
±1.9 ±1.7 ±2.0 ±2.0 ±2.0 ±2.2 ±2.0 ±2.9 ±1.9 ±1.8 ±1.8 ±1.6
Pavp, pg/mliter 3.09 1.22 1.27 1.25 1.24 1.24 <.5 <.5 <.5 <.5 <.5 <.5
±0.4 ±0.25 ±0.23 ±0.15 ±0.20 ±0.21
PIatAVP, pg/muter 7.78*** 747*** 777*** 6.93*** 7.27*** 7.64*** 2.91 1.8 1.9 1.6 1.5 1.5
±1.49 ±1.47 ±1.61 ±1.51 ±1.37 ±1.49 ±0.7 ±0.8 ±0.7 ±0.6 ±0.5 ±0.5
V. mliter/min .91 1.01 l.97** 1.85 1.23 .9 .74 3.33 4.22 2.51 1.62 1.21
±.18 ±.20 ±.31 ±48 ±.2l ±.l5 ±.21 ±1.52 ±.75 ±.42 ±.41 ±.14
Uosm, mOsm/kg H20 510** 476*** 377** 363 450*** 450*** 395 232 190 210 191 231
±28 ±41 ±46 ±66 ±45 ±43 ±25 ±51 ±40 ±34 ±22 ±40
Cosm, muter/mm 1.61 1.64 2.34 1.81 1.84 1.49 1.03 2.0 2.57 1.74 1.01 1.01
±.27 ±36 ±41 ±.32 ±35 ±.31 ±29 ±.55 ±.64 ±.3 ±.24 ±.21
CH2O,mliter/min —.63 .026 —.29 +1.33 +1.65 +.77 +.78 +54
±.12 ±.19 ±.33 ±.54 ±.22 ±.17 ±.11 ±1.1 ±.72 ±0.37 ±.23 ±.2
Values are mean ± SEM. Symbols are: * P < 0.05; ** P < 0.02; *** P < 0.005 (Group I vs. Group II); 1: the value for this characteristic was
the criterion for classifying the patients into two groups; V = urinary flow rate.
a
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Fig. 1. The relationship of plasma A VP to plasma effective osmolality in
the two groups of patients with congestive heart failure. The area with
vertical bars is the 99% confidence limit of the regression line calculated
from the values of 19 normal subjects. (Pavp = 0.16 (Eosm—264,8), N
= 163, r = 0.62). Values for Group I patients are represented before
(solid line) and after (interrupted line) vasodilator therapy. In each case,
basal values (1) and values 1 hr after the waterload (2) are represented.
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levels were not suppressed to undetectable values during the
waterload procedure as occurs in normal subjects at these low
Eosm and PNa (Table 1, Figs. 1 and 2). However, a significant
decrease in Pavp was observed with the marked hypo-osmola-
lity following the water load. P1atAVP levels remained rela-
tively unchanged during the waterload in Group I, and were
always significantly higher than Group II values (P < 0.005)
(Table 1).
The differences in Pavp and PIatAVP between the two groups
Fig. 2. The relationship of plasma A VP to plasma sodium in the two
groups of patients with congestive heart failure. (Pavp = 0.23
(PNa—135.6), N = 163, r = 0.54). Refer to Fig. I for symbols.
were accompanied by differences in water excretion, hemody-
namic and hormonal parameters.
As shown in Table 2, Group I patients excreted only 3 1.4% of
the waterload as compared to 57.1% for Group II (P < .05) in
spite of similar GFR (55.4 ± 4.9 vs. 53.7 ± 10.4 mliter/min/
I .73m, NS). As described above, the Group I patients were
more severely hyponatremic (133.5 vs. 136.5 mEq/liter, P <
0.05) and hypo-osmolar (Eosm: 262.3 ± 1.9 vs. 268 ± 1.02
mOsm/kg H20, P <0.05); yet, their minimal urinary osmolality
(Uosm) was higher (371 ± 36 vs. 162 ± 29 mOsmlkg H20, P <
.001) and, their maximum free water clearance was lower
(—0.04 ± .27 vs. 2.0 ± 0.65 muter/mm, P < 0.01). Osmolar
clearances (1.75 ± 0.2 vs. 1.61 ± 0.22 mliter/min, NS) were
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Table 2. Water excretion, hemodynamic and biochemical characteristics of the two groups of patients studied.
GroupN= ia17 GroupN= 11b8 P
Water excretion, % 31.4 3.2 57.1 7.3 <0.005
Minimal urinary osmolality, mosm/kg 1120 371 36 162 29 <0.001
Maximum free water clearance, muter/mm —0.04 .28 2.03 0.65 <0.01
Osmolar clearance, muter/mm 1.75 0.2 1.61 0.22 NS
Creatinine clearance, mliter/min/1.73 m2 55.4 4.9 53.7 10.4 NS
Cardiac index, liter/minIm2 1.9 0.1 2.47 0.2 <0.05
Pulmonary wedge pressure, mm Hg 30.2 1.4 21.7 1.5 <0.02
Right atrium pressure, mm Hg 13.2 1.2 10.2 1.3 NS
Mean arterial blood pressure, mm Hg 85.8 2.7 90.8 4.0 NS
Pulse, beats/mm 81 3 82 5 NS
Plasma renin activity, nglmliter/hr 4.4 0.7 1.99 0.4 <0.01
Plasma aldosterone, ngldliter 74.1 11.6 10.2 2.1 <0.001
Arterial PO2, mm Hg 80.3 2.7 80.8 5.9 NS
Values are mean SEM.
a High Pavp levels.
b Undetectable Pavp levels.
similar between the two groups. The detailed characteristics of
water excretion in the two groups of patients during the first
waterload study are presented in Table 1.
CI was lower (1.9 0.1 vs. 2.47 0.3 liter/min/m2, P < .05)
and PCPW was higher (30.2 1.4 vs. 21.7 1.5 mm Hg, P <
0.02) in the Group I patients. There were no differences in RAP,
MAP or pulse between the two groups of subjects (Table 2).
Finally, PRA and aldosterone levels were found to be signif-
icantly higher in Group I than the Group II patients (4.4 0.7
vs. 1.99 0.44 ng/mliter/hr, P < 0.01; 74.1 11.6 vs. 10.2
2.1 ng/dliter, P < 0.001) (Table 2). Prior to the discontinuation
of all diuretics for 24 hr, Group I patients received 151 17.3
mg of furosemide per day as compared to 100 17 mg of
furosemide per day for Group II patients (P < 0.02). Arterial
PO2 was found to be similar between the two groups (80.3 2.7
vs. 80.8 5.3 mm Hg, NS, Table 2).
Consequences of improvement of cardiac hemodynamics on
renal water excretion and hormonal characteristics
Patients were randomly assigned to receive either captopril
or prazosin. Eleven patients (eight from Group I, three from
Group II) received captopril and 14 patients (nine from Group I,
five from Group H) received prazosin (Table 3).
In Group I patients during afterload reduction, CI increased
from 1.9 to 2.1 liter/min/m2 (P < 0.001), MAP decreased from
85.4 to 80.6 mm Hg, (P < 0.02), PCWP decreased from 30.2 to
26.7 mm Hg (P < 0.001) and systemic vascular resistance
decreased from 1905 to 1550 dynes x s1 x cm5(P <0.001);
RAP (13.1 to 12.3 mm Hg) and GFR (55.4 to 57.7 muter/minIm2)
did not change. The amount of furosemide used between the
two waterload studies in Group I patients was similar before
and after vasodilator therapy (151 17.3 mg vs. 155 18 mg,
NS).
As demonstrated in Table 3, Group I patients treated with
captopril did not differ from Group I patients treated with
prazosin in regard to control or experimental values for CI,
PCWP, RAP, percentage of waterload excreted, minimal
Uosm, Pavp or PIatAVP. As expected, the only difference
observed in these patients were changes in the renin—angi-
otensin—aldosterone parameters: Group I patients treated with
captopril increased their PRA from 4.15 0.9 to 11.1 1.7
ng/mliter/hr (P < 0.01) and decreased their PA from 81 12.6
to 30 5.4 ngldliter (P < 0.005). In Group I patients treated
with prazosin, no significant changes were observed for either
PRA (4,64 1.0 to 5.15 1.1 ng/mliter/hr, NS) or PA (68.0
19.3 to 49.9 11.1 ng/dliter, NS).
In Group I patients, the percent of water excreted increased
from 31 to 52% (P < 0.001), minimal UOsm decreased from 375
35 to 208 27 mOsmlkg H20 (P < 0.001) (Table 3). Basal
UOsm were also significantly different: 482 28 mOsm/kg H20
in the control condition vs. 395 25 mOsm/kg H20 during the
vasodilator therapy (P < 0.05). However osmolar clearances
were similar. Maximum free water clearance increased from
—0.04 0.27 to 1.01 1.24 mliter/min (P < 0.01). During
afterload reduction with vasodilator, Pavp levels were signifi-
cantly lower before and during the experimental waterload, as
compared to the preceding control study at times 0, 4 and 5
hours (Tables I and 4). During afterload reduction, PIatAVP
levels also decreased significantly (P < 0.005) before and at
each hour during the waterload period (Tables 1 and 4). The
detailed characteristics of this second waterload in Group I and
II patients are presented in Table 4.
In the smaller number of Group II patients, non-significant
changes were observed for CI (2.5 to 2.8 liter/min/m2), PCWP
(21.7 to 21.9 mm Hg), RAP (10.2 to 10.8 mm Hg), SVR (1659 to
1393 dynes x s1 X cm5) and GFR (53.7 10 to 63.5 10.6
mliterlminll .73 m). In Group II patients, minimal UOsm de-
creased significantly during the waterload from 162 29 to 118
22 mOsmlkg H20 (P < 0.005), but without any significant
changes in the percentage of waterload excreted (57 7.3 to 75
8.3, NS). Basal urinary osmolalities were not significantly
different: 395 25 mOsm/kg H20 in the control condition vs.
316 47 mOsm/kg H20 during the vasodilator therapy (Table
4). Also, osmolar clearances were found to be similar: 1.61
0.22 mliter/min during the control waterload vs. 1.58 0.47
mliter/min during the experimental waterload with vasodilator
therapy. Of interest, in Group II patients, Pavp remained
suppressed during the second waterload as well as PIatAVP
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Table 3. Hemodynamics, water excretion and hormonal values of Group I patients according to their therapy (captopril or prazosin).
Patients on Patients on
captoprilN = 8
prazosinN = 9 P value
(exp captopril vs.
Combined data for
group I patients P value for
group I patients
C Exp C Exp exp prazosin) C Exp (C vs. Exp)
Cardiac index, 1/minIm2 1.91 2.09* 1.89 2.13* NS 1.91 2.11
±0.1
<0.001
PCWP, mm Hg 31.3 27.7* 29.24 25.9* NS 30.2 26.7 <0.001
RAP, mm Hg 14.8 13.6
1.97 1.5
11.71 11.0
1.45 1.24
NS 13.2 12.8
1.2
NS
%H20 excreted 27.2 42.6* 35.2 59.6* NS 31.4 52 <0.001
minUosm, mOsm/kg 1120 399 240* 354 180* NS 375 208 <0.001
Pavp, pg/mliter 3.4 1.9* 2.81 1.55* NS 3.1 1.8 <0.01
PIatAVP, pg/mliier 9.04 6.4* 6.8 4.1*
1.4
NS 7.8 5.1
1.5 1.1
<0.005
PRA, ng/mliter/hr 4.15 11.07*
1.67
4.64 5.15 <0.001 — — —
PA, ng/dliter 80.9 30.0* 68.0 49.9 NS — — —
Values are mean SEM. * P < 0.05 (control period vs. experimental period).
Table 4. Plasma sodium (PNa), effective plasma osmolality (Eosm), vasopressin levels and characteristics of water excretion in the two groups
of cardiac patients during the second waterload study (vasodilator therapy).
Time post H20,
Group I, N = 17 Group II , N = 8
basal basal (0)
hr (0) 1 2 3 4 5 1 2 3 4 5
PNa, mEqiliter 132.5 127.8 130.6 131.8
1.0
132.6 132.9 135.7 132.7 134.5 134.8 136.0
1.7
136.9
Eosm, mosm/kg I120 260.5 249.6 254.2 257.4 257.8 257.5 265.1 258.5 260.8 261.7 263.0 262.5
Pavp, pg/mliter l.81*** 0.80 0.80 0.84 0.75* 0.74* <.5 <.5 <.5 <.5 <.5 <.5
PIatAVP, pg/mliter 5.12*** 393** 43*** 4.6*** 44*** 44*** 1.03* 1.06 1.16 1.4 1.06 1.07
V. mliter/min .96 1.59 2.72 2.89 1.82 1.58 1.15 3.52 4.39 3.6 2.96 2.5**
Uom, mOsm/kg 1120 407** 331* 253* 201* 213*** 276*** 316 207 179 156 155 165
Cosm, mliterlmin 1.38 1.72 2.06 1.89 1.25 1.31 1.04 1.79 1.88 1.55 1.47 1.46
CH2O, mliter/min —0.42 —0.13 0.66** 1.00 0.56*** 0.27** 0.11 1.73 2.51
1.0
2.05 1.49 1.04
P < 0.05; ** p < 0.025; P< 0.01 (control waterload values—Table I—vs. second waterload values)
(Table 4). Basal PIatAVP was significantly different after vaso-
dilator therapy (1.03 0.37 vs. 2.19 0.68, P < 0.05). Basal
arterial P°2 did not change after vasodilator therapy in either
group of patients (80.3 2.7 vs. 85.4 5.9 in Group I patients;
80.8 5.9 vs. 75.5 4.5 mm Hg in Group II patients).
Using a multiple regression analysis on the 50 waterload
studies performed (that is, 25 control waterloads and 25 exper-
imental waterloads after vasodilator therapy), we found that
plasma AVP and platelet AVP (mean waterload value for each
individual patient) were positively correlated with minimal
urinary osmolalities (respectively r = 0.62, P< 0.001; r 0.54,
P < 0.001, N 50). Also an inverse correlation was found
between Pavp and the percentage of the waterload excreted (r
= —0.45, P < 0.001, N 50). Finally, Pavp was found to be
inversely correlated to LVSWI (r =
—0.27, N = 50, P = 0.05).
No significant correlation could be established between Pavp
and other humoral or hemodynamic parameters. Also, the
percentage of the water load excreted was not significantly
correlated with GFR (r = 0.25, N = 50).
Discussion
The present results confirm earlier findings using radio-
immunoassay techniques that plasma vasopressin concentra-
tion is elevated in many patients with congestive heart failure
and hyponatremia (5—10]. As previously reported [51, however,
some patients have higher levels of plasma osmolality and
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plasma sodium concentrations and yet plasma vasopressin was
not detectable. In an earlier study, seven of 37 hyponatremic
patients with congestive heart failure also did not have detect-
able plasma vasopressin levels as measured by another sensi-
tive radioimmunoassay [5]. The seven patients with undetect-
able plasma vasopressin concentration also had less severe
hyponatremia and hypo-osmolality than the remaining 30 pa-
tients. It was therefore suggested that non-osmotic stimulation
of AVP occurred in the remaining thirty patients secondary to a
more profound decrease in cardiac output, and thus in effective
arterial blood volume. Support for this hypothesis was that the
30 patients with the detectable plasma AVP concentration had
significantly higher blood urea nitrogen, serum creatinine, and
serum creatinine to blood urea nitrogen ratios as an index of
more severe impaired cardiac function and renal hypoperfusion
[5]. There were, however, no measurements of cardiac index,
intracardiac pressures or hormonal concentrations, as indices
of diminished effective arterial blood volume in this previous
study [5].
The results of the present studies provide substantial support
for the hypothesis that hyponatremic patients with detectable
AVP concentrations have more severe impairment in cardiac
function than those patients with congestive heart failure and
undetectable plasma AVP concentrations. Specifically, the 17
patients (Group I) with detectable plasma AVP levels had
significantly lower cardiac indices, higher pulmonary capillary
wedge pressures, and higher plasma renin activity and aldoste-
rone concentrations than the Group II patients with undetect-
able AVP levels. The Group I patients also had higher levels of
PIatAVP. It is unlikely that during the days preceding the
discontinuation of diuretics, the use of different doses of
furosemide between Group I and Group II patients could
explain our vasopressin results. Specifically, the Group I pa-
tients had higher PCWP, thus, cardiac dysfunction rather than
excessive diuretic use seemed to account for the non-osmotic
release of vasopressin in these patients.
In the Group II patients with congestive heart failure plasma
AVP concentrations were undetectable, and yet an impairment
of water excretion was present (52% excreted in five hours).
The most likely interpretation is that non-AVP factors mediate
this disturbance in renal water excretion. Such non-AVP fac-
tors seem most likely to be of an intrarenal nature which would
diminish fluid delivery to the distal diluting segment of the
nephron. In the present study, patients in both Groups I and II
exhibited diminished glomerular filtration rates and most likely
also had enhanced rates of proximal sodium and water reab-
sorption, as has been demonstrated in experimental heart
failure [21]. Another contributing factor to the impaired water
excretion in these patients could be minimal plasma concentra-
tions of AVP which were not detectable even with the present
sensitive radioimmunoassay techniques. Such minimal plasma
AVP concentrations in patients with cardiac failure might also
be associated with increased collecting duct sensitivity. In
earlier studies, it is clear that with the less sensitive bioassay
technique biologically important vasopressin was not detect-
able; while this seems much less likely with radioimmunoassay
techniques which demonstrate a sensitivity to plasma AVP
concentration of0.5 pglmliter, it is still possible. This possibility
of the presence of unmeasurable but physiologically important
vasopressin was however given some potential credence in the
present study, since platelet AVP levels were detectable in the
Group II patients even though plasma levels were undetectable.
This observation is particularly important since plasma from
patients with complete central diabetes insipidus demonstrated
neither measurable plasma nor platelet AVP, The clinical
availability of specific antagonists to the hydro-osmotic action
of AVP [22, 23] may be necessary to answer this question
definitively.
in any case, the present results clearly demonstrate that
patients with more severe impairment in cardiac function ex-
hibit higher plasma AVP concentrations and more severe im-
pairment in water excretion. Additional support for a cause and
effect relationship between the impaired cardiac function, the
elevated plasma AVP concentration, and the impaired water
excretion was obtained in the vasodilator studies. It was
reasoned that if diminished cardiac output decreased effective
arterial blood volume and stimulated the non-osmotic release of
AVP, then improvement in cardiac function secondary to
afterload reduction should suppress plasma AVP levels and
improve water excretion. Two different vasodilators were used
so as to exclude any non-specific drug effect, and the results
were the same with both agents. In Group I patients with
detectable plasma AVP concentrations, afterload reduction
with either vasodilator was associated with a significant fall in
plasma AVP before and during the waterload; platelet AVP
levels were also significantly lower when these patients were
treated with either captopril or prasozin. This suppression of
plasma and platelet vasopressin concentrations was associated
with enhanced excretion of the acute waterload (31 to 52%, P <
0.001) and no significant change in glomerular filtration rate.
This interpretation is supported by the significant positive
correlation, for the entire group of patients, between Pavp and
minimal Uosm (r = 0.62, P < 0.001). These findings are most
compatible with cardiac output as the major determinant of
effective arterial blood volume in patients with congestive heart
failure. In favor of this interpretation is the negative correlation
between Pavp and left ventricular stroke work index (r =
—0.27, P = 0.05, N = 50). The enhanced water excretion and
suppression of plasma and platelet vasopressin concentrations
were associated with no change in right atrial pressure, and
pulmonary capillary wedge pressure, an index of left atrial
pressure, decreased. A fall in left atrial pressure would be
expected, if anything, to be associated with a rise in plasma
AVP concentrations [24—26]. A role of the renin—angiotensin
system in the suppression of plasma AVP and improvement in
water excretion also did not seem likely. The two vasodilators
exerted different effects on the renin—angiotensin system:
captopril increased renin and suppressed angiotensin 11 forma-
tion, and prasozin did not alter plasma renin activity. The latter
effect may have been related to the counterbalancing effect of
prasozin to improve hemodynamics, thereby obscuring the
activation of the renin—angiotensin system. In any case, the two
vasodilators exerted different effects on the renin—angiotensin
system, and yet both suppressed plasma and platelet AVP
concentrations and improved water excretion. This observation
is not compatible with the renin—angiotensin system as the
primary determinant of AVP release in congestive heart failure.
In this regard, in man it has been clearly shown that tilting at
45°, another maneuver which should decrease effective arterial
blood volume, stimulates vasopressin release to a comparable
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degree in the presence and absence of suppressed renin with a
beta adrenergic blockade [27].
The pathway whereby enhanced cardiac function improved
the suppression of vasopressin and water excretion during the
water load in the Group I patients was also not due to increased
arterial pressure in the high-pressure baroreceptors in the
arterial circulation (that is aortic arch and carotid barorecep-
tors) since mean arterial pressure decreased slightly (—5 mm
Hg) during the afterload reduction using vasodilators. It is,
however, possible that the putative ventricular receptors mod-
ulating vasopressin release [28, 291 may sense an improved
stroke volume and cardiac output during vasodilator therapy,
and thereby mediate the suppression of vasopressin release. In
contrast to our results, Uretsky et al [11] acutely improved
cardiac index in a series of patients with CHF without signifi-
cant changes in plasma AVP levels. However, in this latter
study, only acute changes were recorded, an observation
difficult to compare with our data obtained 48 hr after progres-
sive titration of vasodilator therapy.
Finally, our results with partial suppressibility of high AVP
levels by the 15 muter/kg waterload in Group I patients (Figs. I
and 2) before and after vasodilator therapy, are in favor of the
concept that hemodynamic stimuli in general and congestive
heart failure in particular may lower the osmotic threshold for
vasopressin release. In this regard, the slope of the line relating
pre and post waterload values (Figs. 1 and 2) was found to be
almost parallel to the confidence limit describing the Eosm/AVP
or the PNa/AVP relationship in our 19 control normal subjects.
In summary, the persistent elevation of plasma and platelet
AVP concentrations in hyponatremic patients with cardiac
failure is associated with lower cardiac indices and higher
plasma renin and aldosterone concentrations as compared to
patients with congestive heart failure and undetectable plasma
AVP concentrations. Afterload reduction with two dissimilar
agents, captopril and prasozin, improved cardiac index; this
improvement in cardiac function was associated with a signifi-
cant suppression of plasma and platelet AVP and improvement
in water excretion. The suppression of plasma and platelet AVP
were not explained by changes in right and left atrial pressure,
mean arterial pressure or the renin—angiotensin system, but
rather the results suggest that cardiac function is the main
determinant of the non-osmotic release of AVP in congestive
heart failure. AVP independent factors also seem to be impor-
tant determinants of water excretion in congestive heart failure
particularly in patients with undetectable AVP concentrations.
The presence of detectable platelet AVP concentrations in
these patients, however, raises the possibility that undetect-
able, but physiologically important, concentrations of AVP
could contribute to the impairment in water excretions in these
patients. The clinical and experimental use of AVP analogues
which antagonize the antidiuretic effect of AVP will be neces-
sary to delineate in a more quantitative way, the AVP depen-
dent and AVP independent factors in the impaired water
excretion in congestive heart failure. The present results,
however, demonstrate that changes in cardiac function modu-
late plasma and platelet vasopressin in patients with severe
congestive heart failure. In Group I patients, high AVP levels
were partially suppressed by the waterload acutely; these
results are therefore compatible with a variety of resetting" of
the osmotic threshold for vasopressin and thirst by diminished
cardiac output in patients with cardiac failure [30, 31].
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